New stem cell research being carried out here could lead to a huge breakthrough in the treatment of chronic kidney disease caused by diabetes.A new €6 million research project will evaluate the clinical safety and efficacy of the next-generation cell therapy discovered by Galway-based Orbsen Therapeutics.The study will be led by Professor Timothy O’Brien, Director of the Regenerative Medicine Institute at the National University of Ireland Galway.
The four-year project will test stromal (stem) cell therapy, called Cyndacel-M, in a clinical trial treating patients in Ireland, Northern Ireland, England and Italy.Chronic this disease is marked by the gradual destruction of kidney tissue over time and is a major cause of sickness and death in the EU.Diabetic this disease is a common complication of diabetes and it is estimated that by 2040 it may affect in the region of 200 million people.In most cases of diabetic kidney damage there is no effective medical treatment.The main treatments are drugs, dialysis and kidney transplants, all of which are very expensive and only provide limited protection against adverse outcomes.Professor O’Brien said he hopes that the stromal cell therapy will stop the progress of diabetic kidney disease.He said: “If predictions prove correct, then our healthcare systems are facing a huge task in managing the complications caused by ever-increasing numbers of patients with diabetes mellitusmellitus.
“Chief among such complications will be kidney disease, which has a huge financial cost in terms of current treatments, and takes a massive personal toll on patients. Diabetes is currently the most common cause of end stage this disease resulting in the need for dialysis or transplantation.“We are confident that by harnessing the most modern approaches in stromal cell therapeutics there may well be a way to halt the progression of diabetic kidney disease using this therapy.”
When this disease occurs it can destroy the tissue of the organs over time when inflammation, caused by the body’s immune system’s response to increased blood flow, plays a large part in the majority of this disease cases.This can lead to kidney damage, scar tissue formation (fibrosis) and loss of kidney function and is a common complication of diabetes mellitusmellitus.
In the second year of the project, a clinical trial will take place in Galway, Belfast, Birmingham and Bergamo, in Italy among 48 patients and the trial will see Cyndacel-M injected into the patients’ bloodstream.the results will be measured in terms of improvements in kidney performance as measured by urine and blood samples.If successful, the researchers will see the disease significantly slowed or halted altogether.